Preliminary Pre-Clinical Evaluation of a Molecule With Anti-Seizure Effects
Jan 7, 2022
Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical & societal burden. We report the first promising result of a new candidate BICS01.
Planegg, Germany - January 7, 2022 /PressCable/ —
Planegg / Martinsried (Germany) – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.
According to the World Health Organization (WHO), Epilepsy is a chronic non-communicable disease of the brain that affects around 50 million people worldwide. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. Drug-resistant epilepsy remains a significant clinical and societal burden, with one-third of people with epilepsy continuing to experience seizures despite the availability of around 30 anti-seizure drugs (ASDs). This figure may be as high as 3 out of 4 in patients with temporal lobe epilepsy (TLE). In addition, many ASDs can have significant adverse effects which may severely impact a person’s quality of life.
Gareth Morris et al. report the preliminary preclinical evaluation of BICS01, a synthetic product based on a natural compound that Bicoll scientist pre-selected, as a potential ASD. In the experiments, BICS01 showed low toxicity and was well tolerated following systemic injection at up to 1,000 mg/kg. The results indicate that BICS01 is able to acutely reduce epileptiform activity in hippocampal networks. In conclusion, BICS01 has promising anti-seizure effects with seemingly limited impact on normal hippocampal function. Further studies are required to translate these findings to achieve in vivo efficacy and to ultimately build up a full preclinical profile for BICS01.
The article is available now at: https://www.frontiersin.org/articles/10.3389/fneur.2021.791608/full .
About Bicoll
The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.
Bicoll offers pre-clinical support with an efficient, multi-disciplinary approach to drug discovery. Dedicated to the discovery and optimization of the highest quality lead compounds, Bicoll provides services to international clients in the pharmaceutical, agrochemical, and related industries. The unique combination of expertise in high-tech natural product chemistry and medicinal chemistry enables Bicoll to increase the quality and quantity of the drug discovery pipeline of partner’s candidate portfolios. For more information: https://bicoll-group.com/
Contact Info:
Name: Maria Lamottke
Email: Send Email
Organization: Bicoll GmbH
Address: 19 Am Klopferspitz, Planegg, Bayern 82152, Germany
Phone: +49-89-82010630
Website: https://bicoll-group.com
Source: PressCable
Release ID: 89059186
More News
More cats abandoned 'due to rising costs'
The shelter has seen a "huge increase" in the number of cats it has taken in, compared to last year.
Who Stands to Gain From an Anthropic I.P.O.
Wall Street banks and chipmakers are among those poised to capitalize on the artificial intelligence giant’s public trading debut.
Why Is Halloween Candy So Expensive?
The average cost of a 100-piece bag has jumped 71 percent in the last five years. Consumers are thinking twice about what they’ll spend.
GM Is Leaving NYSE for the Nasdaq After More Than 100 Years
After more than 100 years on the New York Stock Exchange, the automaker is shifting its listing to the Nasdaq, which is home to many technology companies.
Minimum wage set to rise but 18-20 year-olds will not get bigger increase
Chancellor John Healey will reveal the new pay rates in the Budget, and has also announced measures to help households with the cost of living.
How the beauty industry is boosting High Streets
Marie Camara believes beauty and personal care businesses play a key role in supporting high streets.
China Steps In to Rescue Stocks, But the Market Continues to Fall
The Communist Party uses a “national team” of state-owned investment funds to stem the market rout. But this time, investors are not sure it will work.
Mbappé sorry for 'ill-judged' Mao remark after backlash in China
The France star had referred to the former Chinese leader as a "dictator" during an interview about memes.
California’s Potential Quartz Ban Pushes Contractors and Retailers to Alternatives
Manufacturers and their customers are using materials made without the clouds of dust that have sickened workers in quartz-cutting shops.
My Co-Worker Is Losing It Over My Religion
Plus: Reader responses to a woman returning to the office after two decades of self-employment.
My Co-Worker Is Losing It Over My Religion
Plus: Reader responses to a woman returning to the office after two decades of self-employment.
First-time buyer wary of Budget housing loan scheme
Luke Anstee has been saving for three years but says rising living costs make home ownership harder.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.